Physician profile
Haley Mccracken
NPI 1427610427
$2,293.10
in general payments reported to CMS, 2019-2025
24 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $300 · 2022: $557 · 2023: $455 · 2024: $561 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,436.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $381.72 | 2021-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $290.08 | 2022-2025 | Leqvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $185.19 | 2022-2025 | Jardiance |
| Corcept Therapeutics | $170.80 | 2022-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $123.57 | 2022-2024 | |
| Amgen INC. | $102.97 | 2022-2025 | Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $98.50 | 2022-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $82.20 | 2024 | Arcalyst |
| Medtronic, INC. | $40.63 | 2023-2025 | Minimed 780g |
| Impulse Dynamics (USA) INC. | $33.90 | 2022 | |
| Abbott Laboratories | $33.55 | 2025 | Tendril |
| Pfizer INC. | $32.76 | 2023-2025 | |
| Scpharmaceuticals INC. | $30.50 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $22.40 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $20.70 | 2025 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $17.05 | 2022 | |
| Lilly USA, LLC | $16.24 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.46 | 2021 | |
| Esperion Therapeutics, INC. | $15.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.50 | 2021 | |
| Cvrx, INC. | $13.25 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $12.98 | 2021 | |
| Abbvie INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Mccracken listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.